SOURCE: ViaDerma, Inc.

September 08, 2017 08:00 ET

ViaDerma, Inc. Eyes Deal to Place its Patent Pending MMJ Technology into 400 Canadian Retail Stores and an on-line store via the Web, through its Management, Marketing and Distribution Partner in Canada

The Company Plans to Sell its Products Through a Distributor with over 400 Retail Stores Who Currently are Selling Medical (MMJ) and Associated Cannabinoid Products that are Accepted and Allowed, and an on-line store via the Web

LOS ANGELES, CA--(Marketwired - September 08, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the President, Dr. Christopher Otiko is working a distribution deal to distribute its Patent Pending products to over 400 retail dispensary outlets in Canada. The Company would combine its Patent pending MMJ technology Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution. The Management Company plans to launch 3 products in the form of a spray application, a roll on application and an ointment application. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2017 & 2018, adding multiple products, including a patch for treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.

"Unlike other similar products on the market, what makes our world class product line unique is having the % of CBD/THC listed on our products, and with our patent pending delivery system we will have more than 95% of the active ingredients absorbed into the skin. Similar competing products have an absorption rate of 5-30%, and often not tested or listed at all," Otiko said.

Earlier this year the Company had signed a formal agreement based on its' initial LOI to work with a Canadian group with expertise in logistics that includes distribution for the new and anticipated products. The Management Company is working closely with ViaDerma and is developing multiple key products for release to market. ViaDerma, President, Dr. Christopher Otiko recently met with the Canadian Company, and was introduced to various companies involved with the Management Company to bring a world class product line to the market. These include a leading social media management company that will help the businesses grow online, a leading Canadian Dispensary company who has assisted with product development who will be carrying the product line, and a leading Canadian skincare Company, that has help create our fresh products without preservatives and harmful toxic ingredients.

"The first is a CBD/THC product that will treat psoriasis and the second is a THC/CBD product that will treat depression and anxiety. Initial discussions and testing have been received well by certain key Canadian dispensaries and they are eager to launch these products once they are finalized. The Management Company expects products to be available for sale in the fall of 2017, both through dispensaries and via an on-line store. We expect significant sales in 2017 & 2018."

The Management Company will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of the CBD's and THC. ViaDerma, Inc. and the management company will continue product testing and continue to target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries as well as launching these products in certain key States within the United States.

About ViaDerma, Inc.

ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD's and THC with the delivery system was filed in 2017. The use of CBD's is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com

Forward Looking Statements

Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.

Contact Information